Abstracts Archive - Page 1019 of 2425 - ACR Meeting Abstracts

Abstract Number: 214 • 2018 ACR/ARHP Annual Meeting
Exploring the Relation between Air Pollution and Disease Activity in Patients with Rheumatoid Arthritis
Tommaso Schioppo¹, Valentina Bollati^2,3, Chiara Favero^2,3, Nicola Ughi¹, Isabella Scotti¹, Valeria Merlino¹, Orazio De Lucia¹, Antonella Murgo¹ and Francesca Ingegnoli^1,3, ¹Division of Clinical Rheumatology, G. Pini Hospital, Milan, Italy, ²EPIGET Lab, Milan, Italy, ³Dept. of Clinical Sciences & Community Health, Università degli Studi di Milano, Milan, Italy
Background/Purpose: Disease remission is considered an achievable target in a significant proportion of patients with rheumatoid arthritis (RA). Nevertheless, diseases flares, that significantly contributes to…
Abstract Number: 215 • 2018 ACR/ARHP Annual Meeting
A Decade Earlier- Onset of Symptoms of RA in the Indian (Asian) Cohort Compared to Dutch Cohort: Based on Meteor, a Global Database
Arvind Chopra¹, Manjit Saluja², Sytske Anne Bergstra³, Toktam Kainifard⁴, Anuradha Venugopalan⁵ and Tom W.J. Huizinga³, ¹Center for Rheumatic Diseases, Pune, India, ²Rheumatology, Research Co-ordinator, Pune, India, ³Department of Rheumatology, LUMC, Leiden, Netherlands, ⁴Rheumatology, Consultant research and Dietitian, Tehran, Iran (Islamic Republic of), ⁵Rheumatology, R & D, Lab, Center for Rheumatic Diseases, Pune, India
Background/Purpose: Reported symptom onset and diagnosis debut in rheumatoid arthritis (RA) patients may be influenced by environmental factors, genetics and gene-environmental interactions, but also by…
Abstract Number: 216 • 2018 ACR/ARHP Annual Meeting
Inflectra and Remicade Use and Cost in Canada Under Provincial Drug Plans in 2016
Cristiano S. Moura¹, Denis Choquette², Gilles Boire³, Vivian P. Bykerk⁴, Carter Thorne⁵, Walter P. Maksymowych⁶, Peter Lakatos⁷, Talat Bessissow⁸, Larry Svenson⁹, Laura Targownik¹⁰, Waqqas Afif⁸ and Sasha Bernatsky¹¹, ¹The Centre for Outcomes Research and Evaluation (CORE), McGill University Health Centre, Montreal, QC, Canada, ²Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Notre-Dame Hospital, Montreal, QC, Canada, ³Rheumatology Division, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁴Hospital for Special Surgery, New York, NY, ⁵University of Toronto, Newmarket, ON, Canada, ⁶Department of Medicine, CaRE Arthritis and University of Alberta, Edmonton, Canada, Edmonton, AB, Canada, ⁷Medicine, Gastroenterology, McGill University, Montreal, QC, Canada, ⁸Gastroenterology, McGill University, Montreal, QC, Canada, ⁹Division of Preventive Medicine, University of Alberta, Edmonton, AB, Canada, ¹⁰Gastroenterology, University of Manitoba, Winnipeg, MB, Canada, ¹¹Divisions of Rheumatology and Clinical Epidemiology, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Inflectra (infliximab) was the first biosimilar for inflammatory bowel disease and/or arthritis, approved by Health Canada on the belief that it is as safe…
Abstract Number: 217 • 2018 ACR/ARHP Annual Meeting
Association between Comorbidities and Socioeconomic Status Among Patients with Rheumatoid Arthritis in Korea
Seunghwan Shin¹, Anna Shin¹, Ji Hyoun Kim², You-Jung Ha¹, Yun Jong Lee¹, Yeong Wook Song³ and Eun Ha Kang¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of (South), ²Department of Internal Medicine, Chungbuk National University Hospital, Chungcheongbuk-do, Korea, Republic of (South), ³Seoul National University College of Medicine, Seoul, Korea, Republic of (South)
Background/Purpose: Increased prevalence of comorbidities in patients with rheumatoid arthritis (RA) compared to general population has been noted in several previous study. This study aims…
Abstract Number: 218 • 2018 ACR/ARHP Annual Meeting
Risk of Serious Infection Associated with TNF Inhibitor Versus Triple Therapy in Rheumatoid Arthritis Patients
Yinzhu Jin¹, Eun Ha Kang², Rishi J. Desai³, Angela Tong¹ and Seoyoung C. Kim^4,5, ¹Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of (South), ³Division of Pharmacoepidemiology and Pharmacoeconimics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Division of Pharmacoepidemiology and Pharmocoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, MA
Background/Purpose: Treatment with tumor necrosis factor inhibitor (TNFi) with methotrexate or triple therapy (MTX, sulfasalazine, and sulfasalazine) is considered in patients with rheumatoid arthritis (RA)…
Abstract Number: 219 • 2018 ACR/ARHP Annual Meeting
Impact of Rheumatoid Arthritis on Influenza-Related Complications: A Population Based Cohort Study
Preethi Gondi Kamma Venkatesh¹ and Xiang Zhu², ¹Internal Medicine, Florida Hospital, Orlando, FL, ²Florida Hospital, Orlando, FL
Background/Purpose: Rheumatoid Arthritis (RA) is associated with increased incidence of seasonal influenza and its complications. Population-based studies on outcomes are lacking. The aim of our…
Abstract Number: 220 • 2018 ACR/ARHP Annual Meeting
Non-Medical Switch to Biosimilars: What Have We Learned?
José Marona^1,2, Santiago Rodrigues Manica^1,2, Carina Lopes^1,2, João Lagoas Gomes^1,2, Tiago Costa^1,2, Agna Neto^1,3, Inês Silva^1,2, Ana Filipa Mourão^1,2, Sandra Falcao^1,2, Margarida Mateus⁴, Paula Araújo¹, Walter Castelão¹, Manuela Costa¹, Jaime Cunha Branco^1,2 and Fernando Pimentel-Santos^1,2, ¹Rheumatology, Hospital de Egas Moniz - Centro Hospitalar Lisboa Ocidental, EPE, Lisbon, Portugal, ²CEDOC, NOVA Medical School, Lisbon, Portugal, ³Rheumatology, Hospital Central do Funchal - Serviço de Saúde da Região Autónoma da Madeira, E.P.E, Funchal, Portugal, ⁴Hospital de Egas Moniz - Centro Hospitalar Lisboa Ocidental, EPE, Lisbon, Portugal
Background/Purpose: Biosimilars intend to be as effective and safe as the originator product and would increase patients’ access to biological agents. The decision for switching…
Abstract Number: 221 • 2018 ACR/ARHP Annual Meeting
Distal Interphalangeal Joint Involvement and Its Association with Disease Activity in Rheumatoid Arthritis (RA): Analysis Based on a Nationwide RA Database in Japan
Tetsuji Sawada¹, Susumu Nishiyama², Mayu Tago³, Koichiro Tahara³, Eri Kato¹, Hiroaki Mori³, Haeru Hayashi³, Toshihiro Matsui⁴, Jinju Nishino⁵ and Shigeto Tohma⁶, ¹Rheumatology, Tokyo Medical University, Shinjuku Tokyo, Japan, ²Rheumatic Disease Center, Kurashiki Medical Center, Okayama, Japan, ³Rheumatology, Tokyo Medical University, Tokyo, Japan, ⁴National Hospital Organization Sagamihara l Hospital, Clinical Research Center for Allergy and Rheumatology, Kanagawa, Japan, ⁵Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan, ⁶National Hospital Organization Tokyo National Hospital, Kiyose, Japan
Background/Purpose: Distal interphalangeal (DIP) joint arthropathy is characteristic of both psoriatic arthritis and osteoarthritis, but it has long been pointed out that DIP joints can…
Abstract Number: 222 • 2018 ACR/ARHP Annual Meeting
Viral Exposures As a Risk Factor for Rheumatoid Arthritis: Summarizing the Evidence
Fatima Kudaeva¹, Janet E. Pope² and Mark Speechley³, ¹Department of Epidemiology & Biostatistics, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, ²Department of Medicine, University of Western Ontario, London, ON, Canada, ³Epidemiology and Biostatistics, Schulich School of Medicine and Dentistry, Western University, London, Canada, London, ON, Canada
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease with a complex etiology. Infections are viewed as environmental triggers of RA. Different viral exposures have been…
Abstract Number: 223 • 2018 ACR/ARHP Annual Meeting
The Effect of Concomitant Diabetes on RA-Related Outcomes: Results from the Acr’s RISE Registry
Huifeng Yun¹, Fenglong Xie¹, Lang Chen¹, Shuo Yang¹, Leticia Ferri², Evo Alemao², Tammy Curtice² and Jeffrey R. Curtis¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: The impact of concomitant comorbidities on RA outcomes is of high interest, and some evidence suggests that patients (pts) with RA and diabetes may…
Abstract Number: 224 • 2018 ACR/ARHP Annual Meeting
Risk of Venous Thrombotic Events in Rheumatoid Arthritis Patients Initiating Tofacitinib or Adalimumab
Huifeng Yun, Fenglong Xie, Lang Chen and Jeffrey R. Curtis, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Recent concern has been raised for a risk for venous thromboembolism (VTE) associated with janus kinase inhibitors among patients with RA who are already…
Abstract Number: 225 • 2018 ACR/ARHP Annual Meeting
U.S. Trends in Hospitalization Rates and Causes and in-Hospital Mortality in Rheumatoid Arthritis Patients, 2000-2014
Namrata Singh¹, Yubo Gao², Elizabeth Field³, Petar Lenert⁴, Jeffrey R. Curtis⁵ and Mary Vaughan-Sarrazin², ¹Internal Medicine, Iowa City VA Medical Center and University of Iowa, Iowa City, IA, ²University of Iowa Hospitals and Clinics, Iowa City, IA, ³Iowa City VA, Iowa City, IA, ⁴333 MRC Dept of Internal Med, University of Iowa, Iowa City, IA, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Over the past two decades, major advances have been made in the treatment of RA, allowing disease remission to become an achievable goal. Although…
Abstract Number: 226 • 2018 ACR/ARHP Annual Meeting
Representation of Elderly People and Women in Rheumatoid Arthritis and Osteoarthritis Trials: A Systematic Review and Meta-Analysis Comparing Clinical Trials with Population-Based Studies
Andriko Palmowski¹, Thomas Buttgereit^1,2, Yannick Palmowski³, Sabrina Mai Nielsen^4,5, Maarten Boers⁶, Robin Christensen^4,5 and Frank Buttgereit¹, ¹Department of Rheumatology and Clinical Immunology, Charité – University Medicine Berlin, Berlin, Germany, ²Department of Dermatology, Venerology and Allergology, Charité – University Medicine Berlin, Berlin, Germany, ³Center for Musculoskeletal Surgery, Charité – University Medicine Berlin, Berlin, Germany, ⁴Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg, Denmark, ⁵Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁶Department of Epidemiology and Biostatistics, and Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Elderly people (as commonly defined by an age of ≥65 years) and women have been reported to be underrepresented in clinical trials of various…
Abstract Number: 227 • 2018 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patients Treated with Abatacept, Rituximab and Tocilizumab in Denmark and Sweden: Risk of Serious Infections
Kathrine Lederballe Grøn¹, Elizabeth V. Arkema², Bente Glintborg¹, Frank Mehnert³, Mikkel Østergaard⁴, Lene Dreyer⁵, Mette Nørgaard³, Niels Steen Krogh⁶, Johan Askling⁷ and Merete Lund Hetland⁸, ¹The DANBIO registry and the Danish Departments of Rheumatology, Copenhagen, Denmark, ²Clinical Epidemiology Unit, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ³Aarhus University Hospital, Clinical Epidemiological Department, Aarhus, Denmark, ⁴The DANBIO registry and the Danish Departments of Rheumatology, Glostrup, Denmark, ⁵Departments of Rheumatology and Clinical Medicine, Aalborg University Hospital and Aalborg University, 9000 Aalborg, Denmark, ⁶ZiteLab ApS, Copenhagen, Denmark, ⁷Unit of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ⁸DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Glostrup, Denmark
Background/Purpose: Safety concerns have been raised regarding the risk of serious infections (SI) with the different available biologic disease-modifying anti-rheumatic drugs (bDMARDs). Little is known…
Abstract Number: 228 • 2018 ACR/ARHP Annual Meeting
Widespread Chronic Use of Proton-Pump Inhibitors and Potential for Drug-Drug Interactions in Rheumatoid Arthritis and Lupus Patients
Daniel Keebler¹, Nicholas Jones¹ and Matthew McEnany², ¹Genentech, Inc., South San Francisco, CA, ²Genesis Research, Hoboken, NJ
Background/Purpose: Poor control of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) can lead to the use of corticosteroids and non-steroidal anti-inflammatories (NSAIDs), which in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].